A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP).

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Radezolid (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms CAP
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 05 Feb 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 06 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top